Key facts
- This page summarizes Gunnar F. Kaufmann's Form 4 filing for Oncternal Therapeutics, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2023, 16:00.
Gunnar F. Kaufmann - 12 Jun 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc.
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 12 Jun 2023
- Net transaction value
- +$9,824
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2023, 16:00:26 UTC
- Prior SEC filing
- 23 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Chase C. Leavitt, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gunnar F. Kaufmann filed Form 4 for Oncternal Therapeutics, Inc. on 14 Jun 2023.
Change
- Previous filing in this sequence was filed on 23 Feb 2023.
- Current net transaction value: +$9,824.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONCT
transaction
Common Stock
Purchase
- Transaction value
- $8,745
- Shares
- +25,000
- Change %
- +37%
- Price
- $0.3498
- Shares after
- 91,726
- Date
- 12 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
ONCT
transaction
Common Stock
Purchase
- Transaction value
- $1,079
- Shares
- +3,000
- Change %
- +3.3%
- Price
- $0.3597
- Shares after
- 94,726
- Date
- 14 Jun 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $0.3448 to $0.3500. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above.